Litcius/Paper detail

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

Vince Biemans, Frank Hoentjen, Marieke Pierik

2020New England Journal of Medicine18 citationsDOIOpen Access PDF

Abstract

Contains fulltext : 220029.pdf (Publisher’s version ) (Open Access)

Topics & Concepts

VedolizumabMedicineUlcerative colitisAdalimumabInternal medicineDermatologyGastroenterologyTumor necrosis factor alphaDiseaseInflammatory Bowel DiseaseMicroscopic ColitisCeliac Disease Research and Management
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis | Litcius